Emcure Pharmaceuticals Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.052x

Emcure Pharmaceuticals Ltd cash flow conversion efficiency. Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.56 Billion ≈ $27.71 Million USD) by net assets (Rs48.84 Billion ≈ $528.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Emcure Pharmaceuticals Ltd (2022–2026)

Cash flow conversion efficiency of Emcure Pharmaceuticals Ltd from 2022 to 2026. This chart illustrates how Emcure Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Emcure Pharmaceuticals Ltd (EMCURE) share price today for real-time trading data and today's change.

Emcure Pharmaceuticals Ltd Cash Flow Conversion Ratio Explained

Emcure Pharmaceuticals Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Emcure Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Emcure Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Also see market cap of Emcure Pharmaceuticals Ltd for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Cabot Corporation NYSE:CBT	0.043x
Masan Group Corp VN:MSN	0.032x
Peyto Exploration&Development Corp TO:PEY	0.074x
Thor Industries Inc NYSE:THO	0.054x
Auras Technology Co Ltd TWO:3324	-0.044x
KINGDEE INT. UNS.ADR/100 F:KDID	N/A
Alm. Brand CO:ALMB	-0.023x
FIELMANN AG (ADR/1/5)O.N. F:FIE1	N/A

Annual Cash Flow Conversion Efficiency for Emcure Pharmaceuticals Ltd (2022–2026)

The table below shows the annual cash flow conversion efficiency of Emcure Pharmaceuticals Ltd from 2022 to 2026. Review Emcure Pharmaceuticals Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-03-31	Rs49.77 Billion ≈ $538.21 Million	Rs8.51 Billion ≈ $91.98 Million	0.171x	-6.86%
2025-03-31	Rs46.42 Billion ≈ $501.97 Million	Rs8.52 Billion ≈ $92.11 Million	0.183x	-47.79%
2024-03-31	Rs31.22 Billion ≈ $337.61 Million	Rs10.97 Billion ≈ $118.66 Million	0.351x	+24.70%
2023-03-31	Rs26.50 Billion ≈ $286.55 Million	Rs7.47 Billion ≈ $80.77 Million	0.282x	-22.43%
2022-03-31	Rs21.14 Billion ≈ $228.64 Million	Rs7.68 Billion ≈ $83.08 Million	0.363x	--

About Emcure Pharmaceuticals Ltd

NSE:EMCURE India Drug Manufacturers - Specialty & Generic

Market Cap

$3.84 Billion

Rs354.87 Billion INR

Market Cap Rank

#4090 Global

#179 in India

Share Price

Rs1871.80

Change (1 day)

+0.36%

52-Week Range

Rs1324.70 - Rs2009.60

All Time High

Rs2009.60